Abstract: Objective: To evaluate the clinical value of intrapleural perfusion of interleukin-2(IL-2),cisplatin(DDP) or the combined therapy for malignant pleural effusion(MPE) patient.Methods: A pooled analysis was taken which based on the data of efficacy and toxicity of treatments in 3 778 MPE patients from 1993 to 2009,1 499 patients were treated with IL-2 alone,708 patients were treated with cisplatin alone,and 1 571 patients were treated by the combined therapy.The clinic randomized control trail data were screened according to the standard of randomized study without other therapies.Three hundred thirty and five patients were in the IL-2 group,513 patients were in the DDP group and 460 patients were in the combined therapy group.Results: In non-randomized study,the effective rate in IL-2 group was 80.05%,the combined therapy group was 81.41%,which were higher than in DDP group with 58.05%.The adverse reaction rates including heating,bone marrow toxicity,chest pain,gastrointestinal reaction,hepatotoxic and nephrotoxicity had significant differences(P 0.01).In randomized study,the effective rate in IL-2 group was 77.01% and the combined therapy group was 84.13%,which were higher than in DDP group with 58.67%(P 0.05).The adverse reaction rates including heating,bone marrow toxicity,chest pain,gastrointestinal reaction,hepatotoxic and nephrotoxicity had significant differences(P 0.01) among 3 groups in randomized study.Conclusions: It has a good effective therapy with IL-2 alone and well tolerated for MPE patients,which could improve the quality of life.